Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC
The recommendation covers the use of the therapy in combination with cetuximab and Folfox as a first-line treatment option for adult patients with BRAFV600E-mutant mCRC. This represents a
The recommendation covers the use of the therapy in combination with cetuximab and Folfox as a first-line treatment option for adult patients with BRAFV600E-mutant mCRC. This represents a
The approval allows Datroway to be used as a first-line treatment for adults with unresectable or metastatic TNBC who cannot receive programmed cell death protein 1 (PD-1) or
The collaboration aims to accelerate hit identification for these companies through a fee-for-success approach. It will combine OpenBench’s AI-based discovery platform with Concept Life Sciences’ expertise in medicinal
First announced last month, the move aims to advance Gilead’s oncology portfolio. Under the agreement, the company acquired all outstanding equity of Tubulis for $3.15bn upfront on a
The site is anticipated to expand the company’s production capacity for iPSC-based research products and services to four times its previous levels. Fujifilm Cellular Dynamics plans to use
The initiative will embed agentic capabilities throughout BMS’ research, clinical, manufacturing, commercial, and corporate operations. It aims to shift from basic conversational AI towards advanced agentic tools within
The move aims to allow pharmaceutical and biotechnology researchers to use AI more effectively by leveraging enhanced bioinformatics tools and curated knowledge bases. The integration also aims to
The deal covers the European Union, Iceland, Liechtenstein, Norway, Switzerland, the UK, and the Middle East and North Africa (MENA) region. Idefirix is used to desensitise adult patients
The designation follows two randomised, controlled Phase III trials that showed significant pain reduction, good tolerability, and no evidence of dependence. A Phase III comparator study found VER-01
Helicons are stabilised, cell-penetrant alpha-helical peptides engineered to interact with intracellular protein targets, including those with flat surfaces unsuitable for traditional small molecule engagement. The partnership will investigate